We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Results of Late-Stage Trial Lead to End of GSK’s HSV Vaccine
Results of Late-Stage Trial Lead to End of GSK’s HSV Vaccine
October 13, 2010
GlaxoSmithKline (GSK) is halting development of Simplirix, a vaccine to prevent herpes in women that showed promise in early trials, but which failed in a pivotal trial.